Protective effect of plasma neutralization from prior SARS-CoV-2 Omicron infection against BA.5 subvariant symptomatic reinfection

Protective effect of plasma neutralization from prior SARS-CoV-2 Omicron infection against BA.5 subvariant symptomatic reinfection

Bibliographic Details
Main Authors:	Xiaosu Chen, Yanli Xu, Yan Xie, Weiliang Song, Ye Hu, Ayijiang Yisimayi, Sijie Yang, Fei Shao, Li Geng, Ying Wang, Hongmei Gao, Yansong Shi, Shuo Zhang, Ronghua Jin, Zhongyang Shen, Yunlong Cao
Format:	Article
Language:	English
Published:	Elsevier 2023-04-01
Series:	The Lancet Regional Health. Western Pacific
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666606523000767

Similar Items

Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023
by: Jianpeng Cai, et al.
Published: (2024-12-01)

Reinfections with Different SARS-CoV-2 Omicron Subvariants, France
by: Nhu Ngoc Nguyen, et al.
Published: (2022-11-01)

Neutralization against XBB.1 and XBB.1.5 after omicron subvariants breakthrough infection or reinfection
by: Jin-Jin Chen, et al.
Published: (2023-04-01)

Omicron subvariant BA.5 efficiently infects lung cells
by: Markus Hoffmann, et al.
Published: (2023-06-01)

The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection
by: Dandan Tian, et al.
Published: (2022-10-01)

Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
by: Xue-Jun Wang, et al.
Published: (2022-12-01)

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection
by: Jingyun Yang, et al.
Published: (2023-06-01)

Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies
by: Delphine Planas, et al.
Published: (2023-02-01)

High Transmission Rates of Early Omicron Subvariant BA.2 in Bangkok, Thailand
by: Sininat Petcharat, et al.
Published: (2023-01-01)

Epidemiological and clinical features of children with the Omicron BA.5.2 subvariant in Guangzhou
by: Feng Li, et al.
Published: (2023-04-01)

Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
by: Tomokazu Tamura, et al.
Published: (2023-07-01)

Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters
by: Peter J. Halfmann, et al.
Published: (2024-03-01)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
by: Aiste Dijokaite-Guraliuc, et al.
Published: (2022-11-01)

Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau
by: Cong Xu, et al.
Published: (2023-01-01)

Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1
by: Sijie Yang, et al.
Published: (2024-04-01)

Research of Epidemiologic Feature and Control of SARS-CoV-2 Omicron Subvariants BA.4 and BA.5
by: Yu WU, Jue LIU, Min LIU, Wannian LIANG
Published: (2022-10-01)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
by: Rune M. Pedersen, et al.
Published: (2022-12-01)

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
by: Mingxi Li, et al.
Published: (2022-12-01)

Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections
by: Naoyuki Miyashita, et al.
Published: (2023-05-01)

Epidemiology and analysis of SARS-CoV-2 Omicron subvariants BA.1 and 2 in Taiwan
by: Li-Teh Liu, et al.
Published: (2023-10-01)

Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark
by: Frederik Plesner Lyngse, et al.
Published: (2022-09-01)

Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
by: Ka-Li Zhu, et al.
Published: (2023-02-01)

Neutralizing Antibodies against the SARS-CoV-2 Ancestral Strain and Omicron BA.1 Subvariant in Dogs and Cats in Mexico
by: Freddy Dehesa-Canseco, et al.
Published: (2023-06-01)

SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread
by: Xinling Wang, et al.
Published: (2023-11-01)

Strong attenuation of SARS-CoV-2 Omicron BA.1 and increased replication of the BA.5 subvariant in human cardiomyocytes
by: Rayhane Nchioua, et al.
Published: (2022-12-01)

Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study
by: Carson K. L. Lo, et al.
Published: (2024-01-01)

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
by: Hiam Chemaitelly, et al.
Published: (2022-06-01)

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
by: Alexander Wilhelm, et al.
Published: (2022-08-01)

Case Report: Omicron BA.2 Subvariant of SARS-CoV-2 Outcompetes BA.1 in Two Co-infection Cases
by: Marija Gjorgjievska, et al.
Published: (2022-04-01)

Clinical characteristics and vaccine effectiveness against SARS-CoV-2 Omicron subvariant BA.2 in the children
by: Xiaohe Li, et al.
Published: (2022-06-01)

Protection from infection and reinfection due to the Omicron BA.1 variant in care homes
by: Saher Choudhry, et al.
Published: (2023-10-01)

Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
by: Hsiao-Ling Chiang, et al.
Published: (2023-07-01)

Comparison of the replication and neutralization of different SARS‐CoV‐2 Omicron subvariants in vitro
by: Yaqing Zhang, et al.
Published: (2023-02-01)

The Omicron BA.2.2.1 subvariant drove the wave of SARS-CoV-2 outbreak in Shanghai during spring 2022
by: Yun Ling, et al.
Published: (2022-09-01)

Omicron-BA.1 Dispersion Rates in Mexico Varied According to the Regional Epidemic Patterns and the Diversity of Local Delta Subvariants
by: Selene Zárate, et al.
Published: (2023-01-01)

Genomic architecture and evolutionary relationship of BA.2.75: A Centaurus subvariant of Omicron SARS-CoV-2.
by: Atia Basheer, et al.
Published: (2023-01-01)

An imported human case with the SARS-CoV-2 Omicron subvariant BA.2.75 in Yunnan Province, China
by: Meiling Zhang, et al.
Published: (2022-12-01)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
by: Hung Fu Tseng, et al.
Published: (2023-01-01)

SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays
by: Alina Seidel, et al.
Published: (2023-04-01)

Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine
by: Wanting Li, et al.
Published: (2023-08-01)